Clinical trial
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal…
NCT00208546 · Dutch Colorectal Cancer Group, Other · Completed
Key facts
| NCT number | NCT00208546 |
|---|---|
| Title | Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer |
| Official title | Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study |
| Lead sponsor | Dutch Colorectal Cancer Group, Other |
| Collaborators | Koningin Wilhelmina Fonds Sanofi Industry Roche Pharma AG Immunicon |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | 21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab |
| Enrollment | 750 |
| Start date | Jun 1, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 2, 2012 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: